Immix Biopharma, Inc. · NASDAQ:IMMX
Immix Biopharma — Investor Presentation (February 2025)
61 slides from Immix Biopharma's investor presentation, February 2025
Slide 1: Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases
Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases February 2025
Slide 2: Disclaimer: Forward Looking Statements & Market Data
Disclaimer: Forward Looking Statements & Market Data This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.
Slide 3: Immix Biopharma Highlights
Immix Biopharma Highlights • NXC-201 could transform the treatment of Relapsed/Refractory AL amyloidosis where no drugs are FDA approved today (~33,000 existing US patients, $3bn market); NXC-201: The only CAR-T in • Ex-US study: 75% (12/16) Complete response (CR) rate in Relapsed/Refractory AL Amyl
Slide 4: Significant Near-Term Milestones
Significant Near-Term Milestones U.S. Ex- U.S. Anticipated Upcoming Milestones Completed Timing NASDAQ IPO 2021 Next NXC-201 Program Update 1H 2025 Formed Cell Therapy R&D taskforce in 2022 Secured global commercial rights for NXC- 201 from Hadassah/Bar-Ilan in 2022 Report interim clinical data read
Slide 5: Pipeline: Only CAR-T in AL Amyloidosis; Tailor-Made for select Immune-Mediated Diseases
Pipeline: Only CAR-T in AL Amyloidosis; Tailor-Made for select Immune-Mediated Diseases Lead Program: NXC-201, a next-generation BCMA-targeting CAR-T for AL Amyloidosis and select immune-mediated diseases Indication Therapy Pre-clinical Phase 1 Phase 2 Upcoming Milestones 2Q/3Q 2025: Report interim
Slide 6: NXC-201 Referenced in June 2024 New England Journal of Medicine Publication
NXC-201 Referenced in June 2024 New England Journal of Medicine Publication Footer Sanchorawala et al. Systemic Light Chain Amyloidosis. New England Journal of Medicine. June 2024. 6
Slide 7: World-Class Team
World-Class Team Management Board of Directors Scientific Advisory Board Helen Adams, CPA Ilya Rachman, MD, PhD Heather Landau, MD Former Prometheus Chief Executive Officer Director, Amyloidosis Program Biosciences Board Member Suzanne Lentzsch, MD, PHD Magda Marquet, PhD Director, Multiple Myeloma
Slide 8: N-GENIUS Platform: Sterically-Optimized CAR-T Construct Drives Differentiated NXC-201 Clinical Profile
N-GENIUS Platform: Sterically-Optimized CAR-T Construct Drives Differentiated NXC-201 Clinical Profile ALL BCMA CAR-TS ARE NOT CREATED EQUAL N-GENIUS PLATFORM Our CAR-T is differentiated based on 3 Key Construct Modifications 1 Proprietary Optimized 2 Proprietary Optimized 3 Proprietary Optimized CD
Slide 9: Proprietary Sterically-Optimized CD3ζ + CD8 Delivers “Digital” Intracellular Signaling
1 Proprietary Sterically-Optimized CD3ζ + CD8 Delivers “Digital” Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration CD3ζ CARs rely on activation of CAR-T cells through CD3ζ derived immunoreceptor tyrosine-based activation motifs (ITAMs), typically 3 ITAM motifs per CAR “In activ
Slide 10: Sterically-Optimized CD8 Hinge: Reduced Cytokine Release
2 Proprietary Sterically-Optimized CD3ζ + CD8 Delivers “Digital” Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration CD8 Hinge NXC-201: Optimized (Decreased) 216,058 >(90%) 4,050 >(60%) Literature: Optimized (Decreased) CD8 CD8 Hinge Flexibility Resulted In: Hinge Flexibility Res
Slide 11: Sterically-Optimized COBRA Binder Ensures High Expression And Binding Affinity
3 Sterically-Optimized COBRA Binder Ensures High Expression And Binding Affinity COBRA Binder HSL VH (GGGGS)5 VL 3.6 HSL LSH LSH VL (GGGGS)5 VH 80 COBRA Binder 1.6 Leads with 76 NXC-201 Heavy Chain COBRA Binder: Heavy Day 10 CAR-T Expansion (10^7) Specific Cytotoxicity (%): JeKo1 Chain – Proven Link
Slide 12: AL Amyloidosis: ~33,000 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs
AL Amyloidosis: ~33,000 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs NXC-201 TARGETS AL AMYLOIDOSIS PLASMA CELLS THAT EXPRESS BCMA ON CELL SURFACE Light chains deposit in organs, damaging organs Light chains produced by Light chains misfold and dysfunctional plasma cells aggregate He
Slide 13: NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (1/2)
NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (1/2) Newly Diagnosed Relapsed/Refractory Newly diagnosed Relapsed/Refractory Estimated relapsed/refractory US Incidence ~4,300 ~3,225 US Prevalence ~33,277 in 2024 (Previously Treated) Eligible R/R ALA Patients ~36
Slide 14: NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (2/2)
NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population (2/2) Prevalence Incidence Standard of Care Autologous stem cell transplant or Newly diagnosed AL Amyloidosis 1st Line US Incidence ~4,300 daratumumab + CyBorD (four drug combo) 1st Line (± clinical development cand
Slide 15: NXC-201 May Be a Curative Treatment for AL Amyloidosis
NXC-201 May Be a Curative Treatment for AL Amyloidosis ALL BCMA CAR-TS ARE NOT CREATED EQUAL AL amyloidosis is caused by dysfunctional plasma cells that can live for years, continuously producing toxic, misfolded amyloid light chain antibody fragments Bone Marrow Normal LLPC Clone 1 (e.g. common col
Slide 16: NXC-201 Designed for High Activity Against Disease-causing AL Amyloidosis Plasma Cells
NXC-201 Designed for High Activity Against Disease-causing AL Amyloidosis Plasma Cells ALL BCMA CAR-TS ARE NOT CREATED EQUAL a) Uneven BCMA expression and b) frail patient condition has historically prevented conventional, approved CAR-T use in AL Amyloidosis NXC-201 was designed and tested for huma
Slide 17: NXC-201 N-GENIUS Platform “Single-Day CRS” Drives AL Amyloidosis Leadership
NXC-201 N-GENIUS Platform “Single-Day CRS” Drives AL Amyloidosis Leadership ALL BCMA CAR-TS ARE NOT CREATED EQUAL NXC-201’s short CRS duration makes it uniquely NXC-201 Anito-cel suitable to treat ALA patients (in whom the #1 source /CARTddBCMA of mortality is heart failure) Others are 4-8x higher C
Slide 18: Overcoming Neurotoxicity
Overcoming Neurotoxicity ALL BCMA CAR-TS ARE NOT CREATED EQUAL LOW VOLUME DISEASE HIGH VOLUME DISEASE NXC-201 Others NXC-201 Others AL Amyloidosis Low volume autoimmune diseases Multiple Myeloma Multiple Myeloma Others are Others are >10x higher ~7-8x higher Anito-cel /CARTddBCMA CABA-201 Ph2 regist
Slide 19: U.S. NEXICART-2 Trial Designed Based on Ex-US NEXICART-1 Trial Experience
U.S. NEXICART-2 Trial Designed Based on ex-US NEXICART-1 Trial Experience NXC-201 clinical data indicate that R/R Amyloidosis patients with preserved heart function are more likely to benefit from treatment Relapsed/Refractory Allows pre-existing severe Allows patients with prior Allows patients wit
Slide 20: NEXICART-2: US CAR-T NXC-201 Clinical Trial
NEXICART-2: US CAR-T NXC-201 Clinical Trial
Slide 21: NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832)
NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832) NEXICART-2 NXC-201 TRIAL INITIATED IN MID-2024 Study design Status • Open-label, single-arm Phase 1b/2 study • Lead site Memorial Sloan Kettering and other US sites started mid-2024 • n=40 patients (majority of which expected to
Slide 22: NEXICART-2: Patient enrollment focused on patients with preserved heart function
NEXICART-2: Patient enrollment focused on patients with preserved heart function Preserved heart function Median (range) Patient # 1 2 3 4 Age 56 67 82 64 66 (56-82) Gender Female Female Male Female - Prior lines of therapy 4 6 2 4 4 (2-6) Follow up (days) 141 113 57 29 85 (29-141) dFLC (mg/L) 65 24
Slide 23: NEXICART-2 Efficacy: Rapid Normalization of Diseased Light Chains within First ~Month
NEXICART-2 Efficacy: Rapid Normalization of Diseased Light Chains within First ~Month; Consistent with Ex-US Dataset NXC-201 dosing 90 0.9 80 0.8 70 0.7 “An early and deep hematologic m-spike (g/dL) 60 0.6 dFLC (mg/L) response has been found to lead to significantly prolonged survival” 50 0.5 40 Car
Slide 24: NEXICART-2 Efficacy: Rapid Normalization of Diseased Light Chains within First ~Month
NEXICART-2 Efficacy: Rapid Normalization of Diseased Light Chains within First ~Month; Consistent with Ex-US Dataset Subject # NX2-001 NX2-002 NX2-003 NX2-004 NXC-201 Dose 150 150 150 450 (million CAR+T cells) AL Amyloidosis Status as of data cutoff Normal Normal Normal Normal Disease Markers Time t
Slide 25: NEXICART-2 Efficacy: Complete Responses in Two Patients and Remaining Two MRD- 10-6
NEXICART-2 Efficacy: Complete Responses in Two Patients and Remaining Two MRD- 10-6; All Patients in Ongoing Response as of Data Cut-off 1 2 3 4 CART cells infused 150 150 150 450 (x106) Best hematologic Pending Pending Complete response (CR) is CR CR response already MRD(-)10-6 already MRD(-)10-6 F
Slide 26: NEXICART-2 Safety: Consistent or Improved Compared to Ex-US Dataset
NEXICART-2 Safety: Consistent or Improved Compared to Ex-US Dataset • No ICANS neurotoxicity of any kind • Grade 2 CRS in one patient, Grade 1 CRS in one patient, both with 1 day duration Patient # 1 2 3 4 CART Cell Dose (x106) 150 150 150 450 Neurotoxicity None None None None Cytokine release syndr
Slide 27: NEXICART-2: Drivers of Complete Response (CR) in relapsed/refractory AL Amyloidosis
NEXICART-2: Drivers of Complete Response (CR) in relapsed/refractory AL Amyloidosis Drives Drives MRD Negativity Normalization of Immunofixation Light Chains Slower (weeks or months) Faster (days or weeks) Complete Response (CR) As of Nov 14 data cutoff, all 4 patients are: either classified as a CR
Slide 28: Single-arm potentially pivotal NEXICART-2 trial designed considering NEXICART-1 and precedents in AL
Single-arm potentially pivotal NEXICART-2 trial designed considering NEXCIART-1 and precedents in AL 2021 daratumumab (DARZALEX) FDA Approval NXC-201 NEXICART-2 Line of Therapy Newly Diagnosed Relapsed/Refractory Standard of Care (SoC) 3-drug combination: Cyclophosphamide, ✓ None (no FDA approvals)
Slide 29: NEXICART-1: Ex-US CAR-T NXC-201 Clinical Trial
NEXICART-1: Ex-US CAR-T NXC-201 Clinical Trial
Slide 30: NEXICART-1: Normalization of Diseased Free Light Chains 30 Days after Dosing
NEXICART-1: Normalization of Diseased Free Light Chains 30 Days after Dosing NXC-201 RAPIDLY ELIMINATES DISEASED AL AMYLOIDOSIS PLASMA CELLS AND EXITS WITHIN ~30 DAYS “An early and deep hematologic response has been found to lead to significantly prolonged survival” – Vaishali Sanchorawala, M.D. Pro
Slide 31: NEXICART-1: 6 patients had pre-existing heart failure; 10 patients had preserved heart function
NEXICART-1: 6 patients had pre-existing heart failure; 10 patients had preserved heart function d PRE-EXISTING HEART FAILURE CAUSES PHYSICALLY IRREVERSIBLE DISTORTION OF HEART STRUCTURE, SHAPE AND SIZE Preserved heart function Pre-existing heart failure Median (range) Patient # 1 2 3 4 5 6 7 8 9 10
Slide 32: NEXICART-1 NXC-201 Produces Durable Complete Responses in Patients with Preserved Heart Function
NEXICART-1 NXC-201 Produces Durable Complete Responses in Patients with Preserved Heart Function Duration of response (ASH 2024) Stage 2 Ongoing response Stage 1 Cardiac death in CR/VGPR Stage 1 Cardiac death while in PD Stage 1 Preserved Stage 3a Discontinued heart function Target For U.S. AL Amylo
Slide 33: NEXICART-1: 75% Complete Response Rate (is the FDA Regulatory Endpoint)
NEXICART-1: 75% Complete Response Rate (is the FDA Regulatory Endpoint) Preserved heart function Pre-existing heart failure Patient # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 CART cells infused 150 450 800 450 800 800 800 800 800 800 800 800 800 800 800 800 (x106) Best hematologic CR CR CR CR CR VGPR
Slide 34: NXC-201: Potential to Expand to Select Immune-Mediated Diseases
NXC-201: Potential to Expand to Select Immune-Mediated Diseases
Slide 35: CAR-T NXC-201 Targets Plasma Cells (antibody factories of the body)
CAR-T NXC-201 Targets Plasma Cells (antibody factories of the body) ANTIBODY FACTORY PLASMA CELLS PRODUCE ANTIBODIES THAT DRIVE IMMUNE-MEDIATED DISEASES AL Amyloidosis Neurology Hematology Rheumatology Vascular Infiltrates and damages heart • Myasthenia Gravis • Thrombotic thrombocytopenic purpura •
Slide 36: NXC-201 BCMA CAR-T targeting is uniquely suited to address Immune-Mediated Diseases
NXC-201 BCMA CAR-T targeting is uniquely suited to address Immune-Mediated Diseases NXC-201 BCMA CAR-T TARGETS LONG-LIVED PLASMA CELLS, WHICH ARE OFF-TARGET FOR CD19 THERAPEUTICS NXC-201 ~80% of all auto-antibodies in immune-mediated disease are produced by long-lived plasma cells… BCMA is expressed
Slide 37: Appendix
Appendix February 2025
Slide 38: Advantages of CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis
Advantages of CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Antibody-drug NXC-201 Bispecifics conjugates 1 One-time treatment NXC-201 uniquely suited for 2 High Complete Response Rates Relapsed/Refractory AL Amyloidosis 3 Low rates of severe infection 4 No ICANS/Neurotoxicity Note: High comple
Slide 39: In AL Amyloidosis, NXC-201 Overcomes Limitations of Other Modalities in Performance and Tolerability
In AL Amyloidosis, NXC-201 Overcomes Limitations of Other Modalities in Performance and Tolerability Challenges of bispecifics/ T-cell engagers NXC-201 overcomes these challenges • No clinical trials with clinical data • 75% CR in relapsed/refractory AL available in relapsed/refractory AL amyloidosi
Slide 40: NXC-201 Clinical Development Plan Through FDA BLA Submissions
NXC-201 Clinical Development Plan Through FDA BLA Submissions RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL TO ENROLL 40 PATIENTS PRIOR TO FDA BLA SUBMISSION Phase 1b/2 NXC-201 Relapsed/refractory NEXICART-1: 16 patients dosed Ongoing: Expected enrollment Relapsed/Refractory AL 40 Patients NEXIC
Slide 41: NEXICART-1: Durable Responses in NXC-201 AL Amyloidosis Clinical Trial
NEXICART-1: Durable Responses in NXC-201 AL Amyloidosis Clinical Trial SWIMMER PLOT ORDER MATCHED TO ASH 2024 PRESENTATION • Complete hematologic response (CR) of 75% (12/16), a precedent approval endpoint based on the only commercial treatment for AL amyloidosis • Ongoing NEXICART-2 US trial target
Slide 42: World-Class Team
World-Class Team Management Board of Directors Business Advisors Scientific Advisory Board Helen Adams, CPA Mary Sue Coleman, PhD Ilya Rachman, MD, PhD Heather Landau, MD Former Prometheus Former Johnson & Johnson Chief Executive Officer Director, Amyloidosis Program Biosciences Board Member Board M
Slide 43: Principal Investigator for NEXICART-2: Heather Landau, MD
Principal Investigator for NEXICART-2: Heather Landau, MD • Director of the Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York. • Authored more than 100 peer-reviewed publications. • Dr. Landau received her medical d
Slide 44: NXC-201 CAR-T cells penetrate tissues and repeat kill disease-causing cells in AL Amyloidosis
NXC-201 CAR-T cells penetrate tissues and repeat kill disease-causing cells in AL Amyloidosis Diseased AL amyloidosis bone These disease-causing plasma AL Amyloidosis pathologic light chains emerge from deep in the marrow contains densely cells generate a high density of bone marrow where they are p
Slide 45: Pathologic Light Chains in AL Amyloidosis are an Antibody Building Block That Are Overproduced
Pathologic Light Chains in AL Amyloidosis are an Antibody Building Block That Are Overproduced by Plasma Cells A LIGHT CHAIN IS A PORTION OF AN ANTIBODY IN AL, PLASMA CELLS PRODUCE TOO MANY LIGHT CHAINS Diseased light chains Light chain portion in AL Amyloidosis: of antibody excessive production by
Slide 46: This Is Pre-Existing Heart Failure in AL Amyloidosis
This Is Pre-Existing Heart Failure in AL Amyloidosis PRE-EXISTING HEART FAILURE CAUSES PHYSICALLY IRREVERSIBLE DISTORTION OF HEART STRUCTURE, SHAPE AND SIZE Pre-existing heart failure Preserved heart function 46 -
Slide 47: Robust Global Sales of CAR-T Continue
Robust Global Sales of CAR-T Continue Sales of Approved CAR-T ($M) Sales of Approved Bispecifics ($M) 4,800 4,800 Yescarta Tecarus Tecvali Blincyto 4,400 Kymriah Carvykti 4,400 Epkinly Lunsumio 4,000 Abecma Breyanzi 4,000 Columvi 3,600 3,600 3,200 3,200 2,800 2,800 2017 – 2024E 2,400 CAGR: 129% 2,40
Slide 48: Amyloid deposits in AL Amyloidosis are cleared naturally after treatment
Amyloid deposits in AL Amyloidosis are cleared naturally after treatment BEFORE TREATMENT 6-MONTHS AFTER TREATMENT Cytotoxic treatments Pre-treatment imaging (vincristine, Post-treatment imaging shows dense amyloid adriamycin, and dexamethasone) shows clearance of amyloid deposits in liver, bone in
Slide 49: Complete Hematologic Response is correlated with longer survival
Complete Hematologic Response is correlated with longer survival COMPLETE HEMATOLOGIC RESPONSE WAS PRIMARY ENDPOINT IN 2021 DARATUMUMAB APPROVAL STUDY AND ONGOING NEXICART-2 TRIAL Complete Hematologic Response (CR) associated with improved survival in AL 2x survival at 48 months for CR vs PR • Compl
Slide 50: MRD- is Correlated with Improved PFS in AL Amyloidosis
MRD- is Correlated with Improved PFS in AL Amyloidosis MRD negativity is associated with improved Progression Free Survival in AL 2x PFS at 36 months for MRD- vs MRD+ (patients with CR or VGPR) • MRD negative patients have 88% 36-month PFS PFS Probability • MRD positive patients have 46% 36-month PF
Slide 51: N-GENIUS Sterically-Optimized CARTs Drive Immix’s Immune-Mediated Disease Leadership
N-GENIUS Sterically-Optimized CARTs Drive Immix’s Immune-Mediated Disease Leadership N-GENIUS Platform Through partnership Hadassah Medical Organization, Jerusalem and Bar-Ilan University, Immix is a pioneer in sterically-optimized CAR-T construct development, driving our next-generation industry-le
Slide 52: N-GENIUS Platform has produced sterically-optimized BCMA CAR-T NXC-201 with COBRA binder and EXPAND technology
N-GENIUS Platform has produced sterically-optimized BCMA CAR-T NXC-201 with COBRA binder and EXPAND technology ALL BCMA CAR-TS ARE NOT CREATED EQUAL N-GENIUS PLATFORM 3 Key Elements Produced NXC-201 NXC-201 Purpose-Built Cell Therapy Evidence EXPAND Technology + COBRA Binder Capture Engine + Relatio
Slide 53: NXC-201 MoA: Sterically-Optimized BCMA-targeted CAR-T
NXC-201 MoA: Sterically-Optimized BCMA-targeted CAR-T NXC-201: STERICALLY-OPTIMIZED BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM NXC-201 NXC-201 — Key Characteristics High Transduction Efficiency 100% BCMA (Ensuring efficient manufacturing) BCMA Expressing % CAR+ Surface *Carvykti data presented at
Slide 54: Proprietary EXPAND Technology and COBRA Binding Domain Are Differentiated Innovations
Proprietary EXPAND Technology and COBRA Binding Domain Are Differentiated Innovations N-GENIUS TECHNOLOGY PLATFORM: STERICALLY-OPTIMIZED BCMA CAR-T NXC-201 Abecma Carvykti CART-ddBCMA NXC-201 with COBRA Binding Domain γ N-GENIUS EXPAND Technology γ Note: Graphic representation. COBRA = Codon Optimiz
Slide 55: NXC-201 Best-in-Class AL Amyloidosis Clinical Results
NXC-201 Best-in-Class AL Amyloidosis Clinical Results Relapsed/Refractory Light chain (AL) Amyloidosis Darzalex Combination Birtamimab NXC-201 (with cyclophosphamide, CAEL-101 Combined with Monotherapy bortezomib, and/or SOC CyBorD dexamethasone) Dosing frequency 1X Weekly Weekly Weekly Patient #s:
Slide 56: Differentiated NXC-201 safety profile validated in historical Multiple Myeloma data
Differentiated NXC-201 safety profile validated in historical Multiple Myeloma data NXC-201 tolerability data in Relapsed/Refractory Multiple Myeloma Cytokine release syndrome ICANS neurotoxicity Cohort 1 (N=6) Cohort 2 (N=7) Cohort 3 (N=50) Overall (n=63) Cohort 1 (N=6) Cohort 2 (N=7) Cohort 3 (N=5
Slide 57: Relapsed/Refractory Multiple Myeloma: Key Inclusion Criteria
Relapsed/Refractory Multiple Myeloma: Key Inclusion Criteria NXC-201 Abecma Carvykti CART-ddBCMA (NEXICART-1 NCT04720313) (pivotal NCT03361748) (pivotal NCT03548207) (pivotal NCT05396885) Prior lines ≥3 different prior lines of therapy including ≥3 different prior lines of therapy including a ≥3 dif
Slide 58: Relapsed/Refractory Multiple Myeloma: Key Exclusion Criteria
Relapsed/Refractory Multiple Myeloma: Key Exclusion Criteria NXC-201 Abecma Carvykti CART-ddBCMA (NEXICART-1 NCT04720313) (pivotal NCT03361748) (pivotal NCT03548207) (pivotal NCT05396885) Prior BCMA therapy No exclusion BCMA targeted therapy Have received any therapy that is targeted to B- Prior B-c
Slide 59: What is autologous chimeric antigen receptor (CAR)-T cell therapy?
What is autologous chimeric antigen receptor (CAR)-T cell therapy? NXC-201 IS A NEXT-GENERATION BCMA TARGETED AUTOLOGOUS CAR-T CELL THERAPY Patient Specific Personalized treatment using patient’s own T cells plasma Genetic Modification Genetically engineered CARs (chimeric antigen receptors) on T ce
Slide 60: N-GENIUS Platform Process
N-GENIUS Platform Process 1 2 3 4 5 Problem Identification Research Group Platform Foundation Candidate Creation Final Candidate CAR-T Toxicity Main Block to Formation N-GENIUS Platform with EXPAND Entire CAR-T construct optimized with N- Selection Widespread Use: Neurotoxicity Technology aims to ac
Slide 61: Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases
Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases February 2025
Immix Biopharma — Investor Presentation (February 2025) on 6ix